Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06782490 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity

Study acronym: MSS
StatusRecruiting
PhasePhase 2
SponsorCelgene
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial sites expanded: 55 → 58 locations Eligibility criteria expanded, about 10 words Show 1 more changeShow less
    • Eligibility criteria expanded, about 10 words
  2. Study sites revised (55)v24 See this version in full on ClinicalTrials.gov ↗
  3. Study sites: 54 to 55v23
  4. Study sites revised (54)v22 See this version in full on ClinicalTrials.gov ↗
  5. Study sites: 53 to 54v21
Show 19 earlier versionsHide 19 earlier versions
  1. Study sites revised (53)v20 See this version in full on ClinicalTrials.gov ↗
  2. Study sites: 54 to 53v19
  3. Study sites revised (54)v18 See this version in full on ClinicalTrials.gov ↗
  4. Primary completion date: Nov 18, 2026 to May 26, 2027 Completion date: Jan 27, 2027 to Jun 9, 2027 · Study sites revised (54)v17 Show 2 more changesShow less
    • Completion date: Jan 27, 2027 to Jun 9, 2027
    • Study sites revised (54)

    See this version in full on ClinicalTrials.gov ↗

  5. Study sites revised (54)v16 See this version in full on ClinicalTrials.gov ↗
  6. Study sites revised (54)v15 See this version in full on ClinicalTrials.gov ↗
  7. Study sites revised (54)v14 See this version in full on ClinicalTrials.gov ↗
  8. Study sites: 53 to 54v13
  9. Study sites: 51 to 53v12
  10. Study sites revised (51)v11 See this version in full on ClinicalTrials.gov ↗
  11. Study sites: 49 to 51v10
  12. Study sites revised (49)v9 See this version in full on ClinicalTrials.gov ↗
  13. Study sites: 48 to 49v8
  14. Study sites revised (48)v7 See this version in full on ClinicalTrials.gov ↗
  15. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Jun 9, 2025 to Jun 5, 2025 · Study sites revised (48)v6 Show 2 more changesShow less
    • Start date changed from estimate of Jun 9, 2025 to Jun 5, 2025
    • Study sites revised (48)

    See this version in full on ClinicalTrials.gov ↗

  16. Primary completion date: Aug 24, 2026 to Nov 18, 2026 Completion date: Nov 2, 2026 to Jan 27, 2027 · Start date: May 30, 2025 to Jun 9, 2025 · Eligibility criteria expanded, about 25 words · 1 morev5 Show 4 more changesShow less
    • Completion date: Nov 2, 2026 to Jan 27, 2027
    • Start date: May 30, 2025 to Jun 9, 2025
    • Eligibility criteria expanded, about 25 words
    • Secondary endpoints revised (12)

    See this version in full on ClinicalTrials.gov ↗

  17. Start date: Mar 14, 2025 to May 30, 2025 Study sites: 44 to 48v4 Show 1 more changeShow less
    • Study sites: 44 to 48
  18. Site contacts updated at 1 of 44 sitesv3
  19. Study sites: 43 to 44v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986368 in participants with Multiple Sclerosis Spasticity
Trial Details
NCT Number NCT06782490
Lead Sponsor Celgene
Conditions Multiple Sclerosis Spasticity
Enrollment 200 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov